10-Q: Scholar Rock Reports Q1 2026 Financials, Apitegromab BLA Resubmitted

Scholar Rock Holding Corporation filed its Q1 2026 Form 10-Q, detailing a net loss of $105.5 million and a significant increase in G&A expenses, while also announcing the resubmission of its apitegromab BLA with a new PDUFA date.

Summary

• Scholar Rock Holding Corporation reported a net loss of $105.5 million for the three months ended March 31, 2026, compared to a net loss of $74.7 million for the same period in 2025.
• Total operating expenses increased by 32.3% to $102.0 million, driven by a 76.7% increase in general and administrative (G&A) expenses to $50.2 million.
• Research and development (R&D) expenses increased by 6.4% to $51.8 million, primarily due to increased costs for apitegromab manufacturing and the initiation of the Phase 2 OPAL trial, partially offset by decreased costs for SRK-181 and SRK-439.
• The company resubmitted its Biologics License Application (BLA) for apitegromab to the FDA in March 2026, which was accepted with a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2026.
• Cash, cash equivalents, and marketable securities increased to $479.9 million as of March 31, 2026, from $367.6 million as of December 31, 2025, supported by proceeds from a new debt facility and at-the-market offerings.
• The company expects its current cash, cash equivalents, and marketable securities to fund operations into 2027, but anticipates needing additional capital for further development and commercialization.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to the increased net loss and significant rise in G&A expenses, despite the positive step of resubmitting the apitegromab BLA. The delay caused by the CRL and the ongoing need for capital are key concerns.

Positives

• The company resubmitted its BLA for apitegromab, which was accepted by the FDA with a PDUFA action date of September 30, 2026.
• Cash, cash equivalents, and marketable securities increased by $112.4 million during the quarter, reaching $479.9 million.
• The company believes its current cash position is sufficient to fund operations into 2027.
• Proceeds from the new debt facility with Blue Owl Capital Corporation provided significant liquidity.
• The company is developing a subcutaneous formulation of apitegromab, with a Phase 1 study showing favorable bioavailability.

Negatives

• The company reported a net loss of $105.5 million for the quarter, an increase of 41.2% compared to the prior year.
• General and administrative expenses increased significantly by 76.7% to $50.2 million, driven by investments in launch readiness.
• The company previously received a Complete Response Letter (CRL) from the FDA in September 2025 related to a third-party fill-finish facility, which caused a delay.
• The company continues to incur substantial operating losses and expects to do so for the foreseeable future.
• The company is seeking partnerships for its additional programs (SRK-181, SRK-373, SRK-256) as it focuses on rare neuromuscular diseases.

Risks

• The regulatory approval process for apitegromab is lengthy, time-consuming, and unpredictable, with potential for delays or approval for only a subset of patients.
• The company has never commercialized a product and is building its commercialization capabilities, which carries execution risk.
• Disruptions at regulatory agencies like the FDA could impact the review and approval of apitegromab.
• Unfavorable pricing and reimbursement decisions in Europe could delay or limit patient access to apitegromab.
• Product development is expensive and uncertain; clinical trials may fail to meet endpoints or reveal safety concerns.
• Reliance on a limited number of third-party manufacturing and supply partners poses risks of supply interruption or quality issues.
• The company may experience difficulties in managing growth and retaining key personnel.
• Failure to protect intellectual property could harm the company's competitive advantage.
• The company has incurred significant net losses and will require additional capital to fund operations and commercialization.
• The trading price of the company's common stock is volatile and subject to wide fluctuations.
• The company's debt facility with Blue Owl Capital Corporation contains covenants that could restrict its operating and financial flexibility.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities to fund its operating expenses and capital expenditure requirements into 2027. However, it anticipates needing additional capital to complete clinical development and commercialization for its current programs. The company expects to continue incurring significant expenses and operating losses for the foreseeable future.

Management Comments

• We expect that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2027.
• We will require additional capital in order to complete clinical development and commercialization for each of our current programs.
• We expect research and development costs for our product candidates to continue to be substantial for the foreseeable future as the development programs progress.
• We expect general and administrative expense to continue to be substantial as we continue to invest in building the infrastructure to support the commercialization of apitegromab.

Industry Context

StockSavvy.ai notes that Scholar Rock's Q1 2026 results reflect the typical high R&D spend and net losses characteristic of early-stage biopharmaceutical companies focused on developing novel therapies for rare diseases. The resubmission of the apitegromab BLA and the new debt financing are critical steps in advancing its lead candidate towards potential commercialization, a process often marked by regulatory hurdles and significant capital requirements.

Legal Proceedings

• The company was not subject to any material legal proceedings during the three months ended March 31, 2026 and 2025.

Stakeholder Impact

• Shareholders may experience dilution due to the exercise of outstanding warrants and stock options.
• The increased G&A expenses and net loss could impact investor confidence and the stock price.
• The company's reliance on third-party manufacturers and potential supply chain disruptions could affect product availability if apitegromab is approved.
• The need for future capital raises could dilute existing shareholders' ownership interests.

Next Steps

• Continue development activities for apitegromab in SMA, including the ONYX and OPAL trials.
• Initiate a Phase 2 study evaluating apitegromab in patients with FSHD in mid-2026.
• Continue research and development activities for the anti-myostatin program, including the Phase 1 clinical trial for SRK-439.
• Seek partnerships for additional programs (SRK-181, SRK-373, SRK-256) and for myostatin inhibition in combination with GLP-1 weight loss approaches.
• Continue to build commercialization capabilities for apitegromab in anticipation of potential FDA and EMA approval.

Key Dates

Recommendation

Scholar Rock's filing shows increased losses and significant G&A spending, indicating a challenging path to commercialization. While the resubmission of the apitegromab BLA is a positive step, the previous CRL and ongoing need for capital introduce considerable risk. The company's cash runway into 2027 provides some buffer, but the lack of revenue and the competitive landscape warrant a cautious approach. Investors should monitor the upcoming PDUFA date and progress on other pipeline candidates.

Keywords

Scholar Rock, SRRK, Apitegromab, SMA, Form 10-Q, Biopharmaceutical, Clinical Trials, FDA, BLA, Neuromuscular Diseases, Myostatin, R&D Expenses, G&A Expenses, Financing, Debt Facility